(b)(4): during processing of this complaint, attempts were made to obtain complete event, patient and device information.Concomitant medical products: stent: 3.5 x 48 mm xience xpedition; xience alpine (2.5x23, 2.5x23).The stent remains in the patient.Investigation is not yet complete.A follow up report will be submitted with all additional relevant information.
|
It was reported that the patient had pre-existing acute myocardial infarction with triple vessel disease.The lesions to be treated were in the left main bifurcation at the left anterior descending (lad), left circumflex (lcx) ostium, and right coronary artery.Blood pressure lowered during rotablation in the lad lesion, which caused a no-reflow afterwards.The puncture site sheath felt loose which caused blood loss in the patient.An urgent blood transfusion was provided.Intra-aortic balloon pump was attempted, but the physician could not pass through the transfemoral.A peripheral arterial occlusive disease stent was implanted successfully.Additionally, three (3) drug-eluting stents (xience xpedition 2.5x48mm, 3.5x48mm and xience alpine 2.5x23mm) were implanted in the lad and (1) (2.5x23mm xience alpine) in the lcx using a v-stenting technique.The patient continued to experience hemorrhagic shock.The next day, the patient died of suspected hemorrhagic shock.An autopsy was not performed.No additional information was provided.
|
(b)(4).The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of death is listed in the xience xpedition everolimus eluting coronary stent systems instructions for use as a known patient effect of coronary stenting procedures.A conclusive cause for the reported patient effect and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|